# RNA-lipoplex

Source: https://onco.cc/terms/rna-lipoplex/  
OnCo record `rna-lipoplex` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An RNA-lipoplex is a particle in which RNA is complexed with lipids. Its behaviour depends on the exact lipids, charge balance and route, so a result for one lipoplex does not transfer to another product.

## Summary

RNA carries negative charge, and positively charged lipid components can associate with it. RNA-lipoplex names a family of formulations, and the final particle need not be positively charged: net charge depends on the balance of RNA and lipid, the ingredients and the preparation. The naming overlaps with lipid nanoparticles, so the actual composition and properties matter more than the acronym.

In one study of the approach, intravenous RNA-lipoplexes were aimed at dendritic cells by adjusting net charge, without adding a molecular ligand; the particles protected RNA from ribonucleases, were taken up and expressed in dendritic cells and macrophages in lymphoid compartments, and triggered interferon-alpha release from plasmacytoid dendritic cells and macrophages, with antigen-specific T-cell responses and tumour rejection in the authors' in vivo experiments (Kranz and colleagues; the abstract also reports a phase I trial in which three people with melanoma had been treated at a low dose when it was published). An innate-immune signal is not antigen expression, antigen-specific immunity or clinical benefit.

The pancreatic cancer vaccine autogene cevumeran shows how specific a lipoplex product is. In the phase I trial each patient's vaccine held two uridine mRNA strands, each encoding up to 10 neoepitopes, formulated in lipoplex nanoparticles of about 400 nm made from the cationic lipid DOTMA and the phospholipid DOPE, given intravenously (Rojas and colleagues, methods). That trial gave atezolizumab and the vaccine to 16 people and then a modified FOLFIRINOX regimen to 15, so it describes one product within a treatment sequence and neither ranks lipoplexes against lipid nanoparticles nor isolates the vaccine's effect.

A commercial cationic-lipid lipoplex reagent shows how far charge and properties can vary. In vitro, eGFP mRNA lipoplexes formed in pure water measured 98.7 to 121.5 nm by dynamic light scattering and had zeta potentials from -14.4 to -58.7 mV across reagent lots, so a cationic lipid does not guarantee a positive particle, and the value was measured for that preparation, medium and lot (Appelbaum and colleagues; canine retina and cell lines, no cancer setting). The same study separates uptake from expression: after subretinal injection eGFP mRNA was detected in all retinal cell types but protein was limited to the retinal pigment epithelium. A product with the same antigen sequence but different lipids or route is not the same product: particle size and route changed where mRNA LNPs went in mice (Di and colleagues), and the Rojas product is described by its own composition, route and protocol.

For messenger RNA, being inside an endosome is not enough: it must reach the cytosol to be translated. The endosomal-release experiments summarised under lipid nanoparticles used LNPs, not lipoplexes, so they do not by themselves describe a lipoplex.

## Fields

- Kind: Term
- Last checked: 2026-11-16
- Also known as: RNA-LPX; RNA lipoplex; lipoplex RNA vaccine; mRNA-lipoplex nanoparticles
- Tags: delivery-vehicle; rna-delivery

## Notes

- Appelbaum and colleagues measured RNA complexation by gel electrophoresis separately from light-scattering size and zeta potential in stated media and reagent lots. Report the assay and denominator behind any complexed or encapsulated fraction, and assess RNA integrity separately. These product measurements do not establish cytosolic release or expression. In a vaccine, expression in an antigen-presenting cell is also an earlier observation than peptide display, antigen-specific recognition or tumour control.
- Multiple RNAs raise separate questions: whether RNA products are mixed, whether RNAs share a formulation, whether individual particles carry both, and whether the same cells express both proteins. Zhang and colleagues used Lipofectamine 2000 to compare premixed eGFP and mCherry RNAs with mixtures of single-RNA lipoplexes. In HeLa cells, the mixture could match the population-average ratio while individual cells showed variable uptake and expression; joint formulation improved the single-cell correspondence. Mouse embryonic-stem-cell-derived retinal organoids and zebrafish embryo hindbrain injections showed the same qualitative contrast. Input ratios were RNA mass ratios, and reporter fluorescence was measured separately from labelled-RNA uptake. The reporters differed in detection and/or expression. Average strand loading and assumed even mixing do not establish every particle's cargo, and fluorescence ratios do not by themselves specify absolute protein molar ratios or functional assembly. This study of reporters and a research reagent does not establish that every carrier or therapeutic RNA mixture behaves the same.
- In a different comparison, Chen and colleagues attached DOTAP/DOPE lipoplexes carrying one mCherry reporter to polymer microbubbles or gave the lipoplexes beside the bubbles. They tested 4T1 cells and intravenously treated female BALB/c mice with subcutaneous 4T1 tumours, six per group. With ultrasound, separate administration gave greater reporter-positive tumour area and signal farther from vessels; attachment favoured vascular and perivascular signal and was more ultrasound dependent in the cell-culture comparison. Tissue percentages measured fluorescent image area, not the fraction of all tumour cells, and distances over 50 micrometres were excluded from the vessel analysis. Off-site signal was lower in spleen with attachment, while liver differences were not statistically significant. This compares a physical delivery assembly, not whether two RNAs enter the same cell; reporter expression does not demonstrate cancer control or clinical safety.

## Sources

- Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.: https://doi.org/10.1038/nature18300
- Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.: https://doi.org/10.1038/s41586-023-06063-y
- Impact of PEGylation and hyaluronan functionalization on lipoplex-mediated mRNA delivery to the canine retina.: https://doi.org/10.1080/10717544.2025.2544688
- Zhang et al.: two-reporter RNA co-encapsulation and single-cell expression (online 2021; issue 2022): https://doi.org/10.1002/advs.202102072
- Chen et al.: microbubble-bound versus co-administered mRNA lipoplexes (2024): https://doi.org/10.1002/advs.202306139

## Connected records

- terms: [Lipid nanoparticles for RNA delivery](https://onco.cc/terms/lipid-nanoparticle/), [Targeted lipid nanoparticles](https://onco.cc/terms/targeted-lnps/)
- technologies: [mRNA and lipid nanoparticle manufacturing](https://onco.cc/technologies/mrna-lnp-manufacturing/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/)
- drugs: [Autogene cevumeran](https://onco.cc/drugs/autogene-cevumeran/)
- key papers: [Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer](https://onco.cc/key-papers/paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023/)

---
JSON: https://onco.cc/api/v1/entities/rna-lipoplex.json